Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 1/2009

01.01.2009 | Article

Citrobacter infections in a general hospital: characteristics and outcomes

verfasst von: G. Samonis, D. E. Karageorgopoulos, D. P. Kofteridis, D. K. Matthaiou, V. Sidiropoulou, S. Maraki, M. E. Falagas

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

In this investigation, we sought to investigate the characteristics of Citrobacter spp. infections. A retrospective cohort study in a 700-bed, tertiary care, university hospital was carried out during the period from June 1994 to January 2006. Seventy-eight patients (70 adults) with Citrobacter spp. isolates were identified. C. freundii was more common (71.8%), followed by C. koseri (23.1%) and C. braakii (3.8%). The most common associated clinical syndromes were urinary tract infections (52.6% of cases, including eight cases of asymptomatic bacteriuria), as well as intra-abdominal (14.1%), surgical site (7.7%), skin and soft tissue (6.4%), and respiratory tract infections (6.4%). In 29.5% of patients, Citrobacter spp. isolates were associated to polymicrobial infections, principally at sites other than the urinary tract. Antibiograms of 38 consecutive Citrobacter spp. isolates (29 C. freundii) were available. Most active agents were colistin (100%), fosfomycin (100%), imipenem (97.4%), gentamicin (89.5%), nitrofurantoin (89.5%), ciprofloxacin (80.6%), and cefepime (73.7%). Most patients (82.1%) had at least one underlying illness. Combination antimicrobial therapy was administered in 28.2% of cases. One patient died during hospitalization. The length of hospital stay was longer in patients with polymicrobial compared to monomicrobial infections (23 versus 13 days, respectively, p = 0.02). The isolation of Citrobacter species, although rather infrequent, was clinically relevant in the great majority of cases. Further attention should be paid to these pathogens.
Literatur
1.
Zurück zum Zitat Janda JM, Abbott SL, Cheung WK, Hanson DF (1994) Biochemical identification of citrobacteria in the clinical laboratory. J Clin Microbiol 32:1850–1854PubMed Janda JM, Abbott SL, Cheung WK, Hanson DF (1994) Biochemical identification of citrobacteria in the clinical laboratory. J Clin Microbiol 32:1850–1854PubMed
2.
Zurück zum Zitat Brenner DJ, O’Hara CM, Grimont PA, Janda JM, Falsen E, Aldova E et al (1999) Biochemical identification of Citrobacter species defined by DNA hybridization and description of Citrobacter gillenii sp. nov. (formerly Citrobacter genomospecies 10) and Citrobacter murliniae sp. nov. (formerly Citrobacter genomospecies 11). J Clin Microbiol 37:2619–2624PubMed Brenner DJ, O’Hara CM, Grimont PA, Janda JM, Falsen E, Aldova E et al (1999) Biochemical identification of Citrobacter species defined by DNA hybridization and description of Citrobacter gillenii sp. nov. (formerly Citrobacter genomospecies 10) and Citrobacter murliniae sp. nov. (formerly Citrobacter genomospecies 11). J Clin Microbiol 37:2619–2624PubMed
3.
Zurück zum Zitat Hodges GR, Degener CE, Barnes WG (1978) Clinical significance of citrobacter isolates. Am J Clin Pathol 70:37–40PubMed Hodges GR, Degener CE, Barnes WG (1978) Clinical significance of citrobacter isolates. Am J Clin Pathol 70:37–40PubMed
4.
Zurück zum Zitat Lipsky BA, Hook EW 3rd, Smith AA, Plorde JJ (1980) Citrobacter infections in humans: experience at the Seattle Veterans Administration Medical Center and a review of the literature. Rev Infect Dis 2:746–760PubMed Lipsky BA, Hook EW 3rd, Smith AA, Plorde JJ (1980) Citrobacter infections in humans: experience at the Seattle Veterans Administration Medical Center and a review of the literature. Rev Infect Dis 2:746–760PubMed
5.
Zurück zum Zitat Lavigne JP, Defez C, Bouziges N, Mahamat A, Sotto A (2007) Clinical and molecular epidemiology of multidrug-resistant Citrobacter spp. infections in a French university hospital. Eur J Clin Microbiol Infect Dis 26:439–441. doi:10.1007/s10096-007-0315-3 PubMedCrossRef Lavigne JP, Defez C, Bouziges N, Mahamat A, Sotto A (2007) Clinical and molecular epidemiology of multidrug-resistant Citrobacter spp. infections in a French university hospital. Eur J Clin Microbiol Infect Dis 26:439–441. doi:10.​1007/​s10096-007-0315-3 PubMedCrossRef
7.
Zurück zum Zitat Arens S, Verbist L (1997) Differentiation and susceptibility of Citrobacter isolates from patients in a university hospital. Clin Microbiol Infect 3:53–57PubMedCrossRef Arens S, Verbist L (1997) Differentiation and susceptibility of Citrobacter isolates from patients in a university hospital. Clin Microbiol Infect 3:53–57PubMedCrossRef
9.
Zurück zum Zitat Altmann G, Sechter I, Cahan D, Gerichter CB (1976) Citrobacter diversus isolated from clinical material. J Clin Microbiol 3:390–392PubMed Altmann G, Sechter I, Cahan D, Gerichter CB (1976) Citrobacter diversus isolated from clinical material. J Clin Microbiol 3:390–392PubMed
10.
Zurück zum Zitat Samonis G, Anaissie E, Elting L, Bodey GP (1991) Review of Citrobacter bacteremia in cancer patients over a sixteen-year period. Eur J Clin Microbiol Infect Dis 10:479–485. doi:10.1007/BF01963933 PubMedCrossRef Samonis G, Anaissie E, Elting L, Bodey GP (1991) Review of Citrobacter bacteremia in cancer patients over a sixteen-year period. Eur J Clin Microbiol Infect Dis 10:479–485. doi:10.​1007/​BF01963933 PubMedCrossRef
12.
Zurück zum Zitat Jones RN, Jenkins SG, Hoban DJ, Pfaller MA, Ramphal R (2000) In vitro efficacy of six cephalosporins tested against Enterobacteriaceae isolated at 38 North American medical centres participating in the SENTRY Antimicrobial Surveillance Program, 1997–1998. Int J Antimicrob Agents 15:111–118. doi:10.1016/S0924-8579(00)00152-7 PubMedCrossRef Jones RN, Jenkins SG, Hoban DJ, Pfaller MA, Ramphal R (2000) In vitro efficacy of six cephalosporins tested against Enterobacteriaceae isolated at 38 North American medical centres participating in the SENTRY Antimicrobial Surveillance Program, 1997–1998. Int J Antimicrob Agents 15:111–118. doi:10.​1016/​S0924-8579(00)00152-7 PubMedCrossRef
15.
Zurück zum Zitat Horan TC, Gaynes RP (2004) Surveillance of nosocomial infections. In: Mayhall CG (eds) Hospital epidemiology and infection control, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, pp 1659–1702 Horan TC, Gaynes RP (2004) Surveillance of nosocomial infections. In: Mayhall CG (eds) Hospital epidemiology and infection control, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, pp 1659–1702
17.
Zurück zum Zitat Shih CC, Chen YC, Chang SC, Luh KT, Hsieh WC (1996) Bacteremia due to Citrobacter species: significance of primary intraabdominal infection. Clin Infect Dis 23:543–549PubMed Shih CC, Chen YC, Chang SC, Luh KT, Hsieh WC (1996) Bacteremia due to Citrobacter species: significance of primary intraabdominal infection. Clin Infect Dis 23:543–549PubMed
18.
Zurück zum Zitat Kim BN, Woo JH, Ryu J, Kim YS (2003) Resistance to extended-spectrum cephalosporins and mortality in patients with Citrobacter freundii bacteremia. Infection 31:202–207PubMed Kim BN, Woo JH, Ryu J, Kim YS (2003) Resistance to extended-spectrum cephalosporins and mortality in patients with Citrobacter freundii bacteremia. Infection 31:202–207PubMed
20.
Zurück zum Zitat Chen YS, Wong WW, Fung CP, Yu KW, Liu CY (2002) Clinical features and antimicrobial susceptibility trends in Citrobacter freundii bacteremia. J Microbiol Immunol Infect 35:109–114PubMed Chen YS, Wong WW, Fung CP, Yu KW, Liu CY (2002) Clinical features and antimicrobial susceptibility trends in Citrobacter freundii bacteremia. J Microbiol Immunol Infect 35:109–114PubMed
22.
Zurück zum Zitat Samonis G, Ho DH, Gooch GF, Rolston KV, Bodey GP (1987) In vitro susceptibility of Citrobacter species to various antimicrobial agents. Antimicrob Agents Chemother 31:829–830PubMed Samonis G, Ho DH, Gooch GF, Rolston KV, Bodey GP (1987) In vitro susceptibility of Citrobacter species to various antimicrobial agents. Antimicrob Agents Chemother 31:829–830PubMed
23.
Zurück zum Zitat Wang JT, Chang SC, Chen YC, Luh KT (2000) Comparison of antimicrobial susceptibility of Citrobacter freundii isolates in two different time periods. J Microbiol Immunol Infect 33:258–262PubMed Wang JT, Chang SC, Chen YC, Luh KT (2000) Comparison of antimicrobial susceptibility of Citrobacter freundii isolates in two different time periods. J Microbiol Immunol Infect 33:258–262PubMed
24.
Zurück zum Zitat Falagas ME, Kasiakou SK (2005) Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 40:1333–1341. doi:10.1086/429323 PubMedCrossRef Falagas ME, Kasiakou SK (2005) Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 40:1333–1341. doi:10.​1086/​429323 PubMedCrossRef
25.
Zurück zum Zitat Nordmann P (1998) Trends in beta-lactam resistance among Enterobacteriaceae. Clin Infect Dis 27(Suppl 1):S100–S106PubMedCrossRef Nordmann P (1998) Trends in beta-lactam resistance among Enterobacteriaceae. Clin Infect Dis 27(Suppl 1):S100–S106PubMedCrossRef
26.
Zurück zum Zitat Park YJ, Park SY, Oh EJ, Park JJ, Lee KY, Woo GJ et al (2005) Occurrence of extended-spectrum beta-lactamases among chromosomal AmpC-producing Enterobacter cloacae, Citrobacter freundii, and Serratia marcescens in Korea and investigation of screening criteria. Diagn Microbiol Infect Dis 51:265–269. doi:10.1016/j.diagmicrobio.2004.11.009 PubMedCrossRef Park YJ, Park SY, Oh EJ, Park JJ, Lee KY, Woo GJ et al (2005) Occurrence of extended-spectrum beta-lactamases among chromosomal AmpC-producing Enterobacter cloacae, Citrobacter freundii, and Serratia marcescens in Korea and investigation of screening criteria. Diagn Microbiol Infect Dis 51:265–269. doi:10.​1016/​j.​diagmicrobio.​2004.​11.​009 PubMedCrossRef
27.
Zurück zum Zitat Kim BN, Lee SO, Choi SH, Kim NJ, Woo JH, Ryu J et al (2003) Outcome of antibiotic therapy for third-generation cephalosporin-resistant Gram-negative bacteraemia: an analysis of 249 cases caused by Citrobacter, Enterobacter and Serratia species. Int J Antimicrob Agents 22:106–111. doi:10.1016/S0924-8579(03)00094-3 PubMedCrossRef Kim BN, Lee SO, Choi SH, Kim NJ, Woo JH, Ryu J et al (2003) Outcome of antibiotic therapy for third-generation cephalosporin-resistant Gram-negative bacteraemia: an analysis of 249 cases caused by Citrobacter, Enterobacter and Serratia species. Int J Antimicrob Agents 22:106–111. doi:10.​1016/​S0924-8579(03)00094-3 PubMedCrossRef
Metadaten
Titel
Citrobacter infections in a general hospital: characteristics and outcomes
verfasst von
G. Samonis
D. E. Karageorgopoulos
D. P. Kofteridis
D. K. Matthaiou
V. Sidiropoulou
S. Maraki
M. E. Falagas
Publikationsdatum
01.01.2009
Verlag
Springer-Verlag
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 1/2009
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-008-0598-z

Weitere Artikel der Ausgabe 1/2009

European Journal of Clinical Microbiology & Infectious Diseases 1/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.